[Treatment of superficial tumors of the bladder].
Superficial bladder cancer includes T1, Ta, TIS transitional cell carcinomas of the TNM classification. These tumors represent a spectrum disease with different biological behavior. Some tumors may recur on the same mode for years, others have a definite metastatic risk in the short range. The main difficulty in the management of these tumors is to predict their potential aggressiveness based on clinicopathological parameters. Their management is based on the initial endoscopy and histopathological analysis. Molecular markers will reach the clinical level in order to better predict the prognosis and improved the non invasive tools for follow-up. For low risk tumors, transurethral resection (TUR) and surveillance allow an adequate tumor control. For high risk tumors, conservative treatment is based on a complete transurethral resection which need confirmation by a second look TUR and prophylactic endovesical instillations of bacille Calmette Guérin (BCG). The response to the first BCG cycle represent a crucial indicator of tumor behavior. For intermediate risk lesions, the advantage of prophylactic endovesical instillations have been finally established either using BCG or chemotherapy (Mitomycine C). However in this setting, various therapeutic modalities (maintenance therapy, dose, repeat cycles) are proposed and their relative efficacy remain to be established. For this later group of tumor it is more likely that the use of maintenance therapy or repeated courses increase the chance of conservative treatment. Other therapeutic modalities exist (oral interferon inductors, photochemotherapy) but remain second line or investigative therapies. In conclusion, progress in the understanding of the natural history of bladder cancer allow a better management of these tumor in order to optimize the ratio between the oncologic efficacy and quality of life.
Patard
J J
JJ
Service d'urologie et centre de recherche Claude-Bernard, hôpital Henri-Mondor, Créteil, France.
Chopin
D
D
Abbou
C C
CC
D000283:Administration, Intravesical; D000782:Aneuploidy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002985:Clinical Protocols; D003558:Cystoscopy; D006801:Humans; D009367:Neoplasm Staging; D012307:Risk Factors; D012737:Sex Factors; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000379:methods
D000970:Antineoplastic Agents